Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Protein Folding01:25

Protein Folding

11.1K
Proteins are chains of amino acids linked together by peptide bonds. Upon synthesis, a protein folds into a three-dimensional conformation, critical to its biological function. Interactions between its constituent amino acids guide protein folding, and hence the protein structure is primarily dependent on its amino acid sequence.
Protein Structure Is Critical to Its Biological Function
Proteins perform a wide range of biological functions such as catalyzing chemical reactions, providing...
11.1K
Protein Folding01:22

Protein Folding

126.3K
Overview
126.3K
Amyloid Fibrils03:03

Amyloid Fibrils

11.6K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.6K
Amyloid Fibrils03:03

Amyloid Fibrils

6.3K
6.3K
Molecular Chaperones and Protein Folding03:00

Molecular Chaperones and Protein Folding

19.6K
The native conformation of a protein is formed by interactions between the side chains of its constituent amino acids. When the amino acids cannot form these interactions, the protein cannot fold by itself and needs chaperones. Notably, chaperones do not relay any additional information required for the folding of polypeptides; the native conformation of a protein is determined solely by its amino acid sequence. Chaperones catalyze protein folding without being a part of the folded protein.
The...
19.6K
Molecular Chaperones and Protein Folding03:00

Molecular Chaperones and Protein Folding

14.8K
14.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dopamine replacement therapy modulates DDC, prolactin and AOC3 levels in Parkinson's disease.

NPJ Parkinson's disease·2026
Same author

Dysregulation of sphingolipid-metabolizing enzymes in Friedreich's ataxia: <i>In vitro</i> and <i>in vivo</i> insights into therapeutic targeting.

iScience·2026
Same author

Mutasynthesis and Antibiotic Activity of Mupirocin Analogues.

Chembiochem : a European journal of chemical biology·2026
Same author

Correction to "Monooxygenase Activity of Indoleamine 2,3-Dioxygenase".

Journal of the American Chemical Society·2026
Same author

Reactive astrocytes mediate toxicity in iPSC derived dopaminergic neurons.

NPJ Parkinson's disease·2026
Same author

Molecular characterisation of extracellular vesicles released by Strongyloides stercoralis infective larvae isolated from a clinical sample.

Parasites & vectors·2026

Related Experiment Video

Updated: Jan 16, 2026

Utilizing Time-Resolved Protein-Induced Fluorescence Enhancement to Identify Stable Local Conformations One &#945;-Synuclein Monomer at a Time
07:56

Utilizing Time-Resolved Protein-Induced Fluorescence Enhancement to Identify Stable Local Conformations One α-Synuclein Monomer at a Time

Published on: May 30, 2021

3.6K

Stabilizing a Native Fold of Alpha-Synuclein with Short Helix-Constrained Peptides.

Richard M Meade1, Scott G Allen1, Amy J Lopez2

  • 1Department of Life Sciences, University of Bath, Claverton Down, Bath BA2 7AY, United Kingdom.

JACS Au
|September 26, 2025
PubMed
Summary

Researchers developed smaller peptides to prevent alpha-synuclein (αS) aggregation, a key factor in Parkinson's disease. The most effective peptide, αS2-12(L6), shows promise for therapeutic development by improving neuronal uptake and stability.

Keywords:
Parkinson’s diseaseamyloid aggregationlipid induced aggregationlipid vesiclespeptide

More Related Videos

Millisecond Hydrogen/Deuterium-Exchange Mass Spectrometry for the Study of Alpha-Synuclein Structural Dynamics Under Physiological Conditions
08:40

Millisecond Hydrogen/Deuterium-Exchange Mass Spectrometry for the Study of Alpha-Synuclein Structural Dynamics Under Physiological Conditions

Published on: June 23, 2022

3.4K
Synthesis and Characterization of 1,2-Dithiolane Modified Self-Assembling Peptides
09:54

Synthesis and Characterization of 1,2-Dithiolane Modified Self-Assembling Peptides

Published on: August 20, 2018

7.7K

Related Experiment Videos

Last Updated: Jan 16, 2026

Utilizing Time-Resolved Protein-Induced Fluorescence Enhancement to Identify Stable Local Conformations One &#945;-Synuclein Monomer at a Time
07:56

Utilizing Time-Resolved Protein-Induced Fluorescence Enhancement to Identify Stable Local Conformations One α-Synuclein Monomer at a Time

Published on: May 30, 2021

3.6K
Millisecond Hydrogen/Deuterium-Exchange Mass Spectrometry for the Study of Alpha-Synuclein Structural Dynamics Under Physiological Conditions
08:40

Millisecond Hydrogen/Deuterium-Exchange Mass Spectrometry for the Study of Alpha-Synuclein Structural Dynamics Under Physiological Conditions

Published on: June 23, 2022

3.4K
Synthesis and Characterization of 1,2-Dithiolane Modified Self-Assembling Peptides
09:54

Synthesis and Characterization of 1,2-Dithiolane Modified Self-Assembling Peptides

Published on: August 20, 2018

7.7K

Area of Science:

  • Neuroscience
  • Biochemistry
  • Drug Discovery

Background:

  • Alpha-synuclein (αS) aggregation into toxic species is central to Parkinson's disease and Lewy body dementia.
  • Targeting intracellular αS aggregation is challenging due to large protein interfaces and poor cell permeability of conventional therapeutics.
  • Peptides offer a promising therapeutic modality due to their intermediate size and potential for cell penetration.

Purpose of the Study:

  • To identify the smallest functional peptide capable of inhibiting αS aggregation and toxicity.
  • To systematically truncate and constrain peptides derived from the αS N-terminal region (αS1-25) to optimize therapeutic properties.
  • To evaluate the impact of helix constraints on peptide efficacy, stability, and cellular activity.

Main Methods:

  • Systematic N- and C-terminal truncation of αS1-25 to reduce peptide size.
  • Introduction of i → i + 4 helix constraints to stabilize α-helical structure.
  • Assessment of peptide binding to αS, inhibition of αS aggregation, serum stability, neuronal uptake, and phenotypic rescue in cellular models.

Main Results:

  • Peptide downsizing achieved a 56% reduction in length while retaining αS binding and aggregation inhibition.
  • Helix constraints significantly improved α-helicity, aggregation inhibition, serum stability, and neuronal uptake.
  • The optimized peptide, αS2-12(L6), demonstrated potent inhibition of αS aggregation and toxicity, with enhanced therapeutic characteristics.

Conclusions:

  • Key amphipathic features and critical residues for αS engagement and inhibition were identified.
  • The helix-constrained peptide αS2-12(L6) represents a highly effective and promising therapeutic candidate for αS-related neurodegenerative diseases.
  • This study provides a roadmap for designing potent peptide-based therapeutics targeting protein aggregation.